Notably, the treatment of TNF-α-activated MDA-MB-231 tumor cells with the proteasome inhibitor MG132, which blocks Nf-κB activity, significantly reduces cell aggregation, while anti-ICAM-1 monoclonal antibodies significantly decrease the number of hetero-aggregates attached to the endothelium [83]. This evidence concerns the gene TNF and neoplasm.